Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
Recruiting now
Conditions studied: Esophageal Cancer
In brief
Despite multimodal therapy, patients with esophageal cancer have poor prognosis with 5-year overall survival around 25%. Considering tumor-related death as main reason for high mortality rate in those patients, treatment-related cardio-pulmonary toxicities could also play a role in this regard. Online adaptive radiotherapy offers the possibility for daily re-planning and therefore helps radiation oncologists to better spare the organs at risk and reduce radiation-induced toxicity. Tha aim of ARTEC is to assess the pulmonary toxicity in patients with esophageal cancer treated with online adaptive radiotherapy.
Key facts
- Study ID
- NCT06361043
- Run by
- Insel Gruppe AG, University Hospital Bern
- People needed
- 30
- Starts
- 2024-04-20
- Expected to finish
- 2027-02-28
- Last updated by the study team
- 2024-04-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent
- Histologically confirmed diagnosis of AC (Adenocarcinoma) or SCC (squamos cell carcinoma) of the thoracic esophagus or gastroesophageal junction (Siewert I-II)
- Patients with cT2-4b cN0 cM0 or cTany cN+ cM0 or any patient with early stage EC ineligible for upfront surgery
- Age >= 18 years old
- Karnofsky Performance Status (KPS) >= 70 or ECOG (Eastern Cooperative Oncology Group) 0 - 1
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with patients before registration in the trial
You may not qualify if…
- Cervical esophageal cancers (15-18 cm from the incisors)
- Definitive clinical or radiologic evidence of metastatic disease
- Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment
- Prior thoracic radiotherapy that would result in overlap of radiation therapy fields
- Induction chemotherapy for the current malignancy prior to RCHT is allowed if last dose is no more than 90 days and no less than 10 days prior to registration
- Pregnant and/or breast-feeding females
Where it is running
- Inselspital, University of Berne, Deparftment of Radio-Oncology — Bern, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.